Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategies to overcome drug resistance using SHP2 inhibitors

28 Mar 2021

Abstract excerpt

, the SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti-cancer drug target, SHP2 regulates many signaling pathways such as RAS-RAF-ERK, PI3K-AKT and JAK-STAT. Meanwhile, SHP2 plays a significant role in regulating immune cell function in the tumor microenvironment. Heretofore, five SHP2 allosteric inhibitors have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Galectins and Cancer Biology
Share to Protein Tyrosine Phosphatases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35024315
DOI: 10.1016/j.apsb.2021.03.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies to overcome drug resistance using SHP2 inhibitorsPMID 35024315Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Functions of Shp2 in cancer.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.Semantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

Targeted degradation of the oncogenic phosphatase SHP2Semantic proximity Read ↗

Targeted Degradation of the Oncogenic Phosphatase SHP2.Semantic proximity Read ↗

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 ProteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.